Steward Partners Investment Advisory LLC Decreases Stock Holdings in GSK plc (NYSE:GSK)

Steward Partners Investment Advisory LLC trimmed its holdings in GSK plc (NYSE:GSK) by 72.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,573 shares of the pharmaceutical company’s stock after selling 73,316 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in GSK were worth $933,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of GSK. FMR LLC lifted its stake in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC lifted its stake in GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC raised its position in shares of GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after buying an additional 833,080 shares during the period. Miller Howard Investments Inc. NY purchased a new stake in shares of GSK during the 4th quarter valued at approximately $23,366,000. Finally, Bridgewater Associates LP raised its position in shares of GSK by 107.3% during the 3rd quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock valued at $39,483,000 after buying an additional 500,010 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GSK has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Morgan Stanley initiated coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, GSK presently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Up 0.9 %

GSK stock opened at $40.41 on Tuesday. The firm has a 50 day moving average price of $35.61 and a 200 day moving average price of $37.13. The company has a market capitalization of $83.74 billion, a PE ratio of 25.41, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Research analysts expect that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a dividend yield of 3.89%. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is presently 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.